J&J
Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.
UK's NICE Approves J&J's Balversa for FGFR3-Altered Urothelial Cancer
The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.
European Commission Approves J&J's Subcutaneous Rybrevant for Certain NSCLC Patients
The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
CHMP Recommends Approval of J&J's Subcutaneous Rybrevant for Certain NSCLC Patients in Europe
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.